Effectiveness of Rehabilitation Interventions for Mobility Impairment in Parkinson's Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Age-related Mobility Decline
- Sponsor
- University of Florida
- Enrollment
- 58
- Locations
- 1
- Primary Endpoint
- Change in temporal variability
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This is an exploratory study designed to investigate the effects of aerobic dual belt treadmill walking versus traditional treadmill exercise on gait performance and functional capacity in older adults at risk for mobility disability. Identifying the relationship between aerobic treadmill exercise (dual belt or traditional) and the recovery of walking abilities will serve to optimize current rehabilitation approaches.
Detailed Description
Participants will be forty-eight older adults with pre-clinical mobility disability who will be randomized into one of three intervention groups: dual-belt treadmill exercise, traditional treadmill exercise, or non-contact control. Prior to and following 16 weeks of therapy, we will observe the participants' performing several functional movements (walking, standing from sitting, sitting from standing, walking up and down stairs) and measure their muscular activity. These performance-based measures will be obtained to determine whether their movement function improves as a result of therapeutic intervention. The participants' absolute performance on any of these tasks does not matter as much as that they make the very best effort on each of the tests. They are welcome to take a break at any point in the testing or training.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 65 and older
- •Gait Speed of ≤ 1m/s
- •Summary score 7-10 on the Short Physical Performance Battery, indicating mild to moderate impairment
- •Sedentary as defined by reporting \<20 min/wk of performing regular physical activity in the past month and \<125 min/wk of moderate physical activity on the CHAMPS-18 questionnaire
- •Willingness to be randomized to any of the treatment groups
Exclusion Criteria
- •Failure to provide informed consent
- •Planned surgery in next year
- •Hospitalization within the past 6 months
- •Smoker \> 1 pack per day
- •Significant cognitive impairment, defined as a known diagnosis of dementia or a Modified Mini-Mental State score \<24
- •Significant cognitive executive impairment, defined as a Montreal Cognitive Assessment (MoCA) score of\<25
- •Progressive, degenerative neurologic disease, e.g., Parkinson's Disease, multiple sclerosis, Amyotrophic lateral sclerosis (ALS)
- •Severe rheumatologic or orthopedic diseases, e.g., awaiting joint replacement, active inflammatory disease
- •Terminal illness with life expectancy less than 12 mos, as determined by a physician
- •Severe pulmonary disease, requiring either steroid pills or injections or the use of supplemental oxygen
Outcomes
Primary Outcomes
Change in temporal variability
Time Frame: baseline and up to 6 weeks following the intervention
Temporal will be determined from kinematic and kinetic measurement methods. Lower values correspond to better walking performance.
Change in Gait Speed
Time Frame: baseline and up to 6 weeks following the intervention
Gait speed will be determined from kinematic and kinetic measurement methods. A low value would indicate a slower walking speed compared to a higher value (faster walking speed).
Change in spatial variability
Time Frame: baseline and up to 6 weeks following the intervention
Spatial will be determined from kinematic and kinetic measurement methods. Lower values correspond to better walking performance.
Secondary Outcomes
- Change in Disability(baseline and up to 6 weeks following the intervention)
- Change in Timed up and Go(baseline and up to 6 weeks following the intervention)
- Change in physical performance(baseline and up to 6 weeks following the intervention)
- Change in cognitive impairment(baseline and up to 6 weeks following the intervention)
- Change in Cognitive impairment of executive function(baseline and up to 6 weeks following the intervention)
- Change in likelihood of falling(baseline and up to 6 weeks following the intervention)
- Change in knee extensor strength(baseline and up to 6 weeks following the intervention)
- Change in ankle plantarflexor strength(baseline and up to 6 weeks following the intervention)
- Change in timed chair rise(baseline and up to 6 weeks following the intervention)
- Change in timed stair climb(baseline and up to 6 weeks following the intervention)
- Change in Ambulatory activity(baseline and up to 6 weeks following the intervention)
- Change in energetic cost of walking(baseline and up to 6 weeks following the intervention)